{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:25:21Z","timestamp":1785295521388,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA170378PQ2, 1U01CA188383-01\/S1"],"award-info":[{"award-number":["CA170378PQ2, 1U01CA188383-01\/S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The\n                    <jats:italic>MYC<\/jats:italic>\n                    oncogene drives T- and B- lymphoid malignancies, including Burkitt\u2019s lymphoma (BL) and Acute Lymphoblastic Leukemia (ALL). Here, we demonstrate a systemic reduction in natural killer (NK) cell numbers in\n                    <jats:italic>SR\u03b1-tTA\/Tet-O-MYC<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>ON<\/jats:italic>\n                    <\/jats:sup>\n                    mice bearing MYC-driven T-lymphomas. Residual mNK cells in spleens of\n                    <jats:italic>MYC<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>ON<\/jats:italic>\n                    <\/jats:sup>\n                    T-lymphoma-bearing mice exhibit perturbations in the terminal NK effector differentiation pathway. Lymphoma-intrinsic MYC arrests NK maturation by transcriptionally repressing\n                    <jats:italic>STAT1\/2<\/jats:italic>\n                    and secretion of Type I Interferons (IFNs). Treating T-lymphoma-bearing mice with Type I IFN improves survival by rescuing NK cell maturation. Adoptive transfer of mature NK cells is sufficient to delay both T-lymphoma growth and recurrence post MYC inactivation. In MYC-driven BL patients, low expression of both STAT1 and STAT2 correlates significantly with the absence of activated NK cells and predicts unfavorable clinical outcomes. Our studies thus provide a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.\n                  <\/jats:p>","DOI":"10.1038\/s41467-020-16447-7","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T06:04:22Z","timestamp":1591337062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies"],"prefix":"10.1038","volume":"11","author":[{"given":"Srividya","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-8393","authenticated-orcid":false,"given":"Aida S.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-7341","authenticated-orcid":false,"given":"Line D.","family":"Heftdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renumathy","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Deutzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadie D. M.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-9690","authenticated-orcid":false,"given":"Daniel F.","family":"Liefwalker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crista","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Liebersbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holden T.","family":"Maecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-523X","authenticated-orcid":false,"given":"Dean W.","family":"Felsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"16447_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","volume":"4","author":"DW Felsher","year":"1999","unstructured":"Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199\u2013207 (1999).","journal-title":"Mol. Cell"},{"key":"16447_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein, I. B. Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 297, 63\u201364 (2002).","journal-title":"Science"},{"key":"16447_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nrc1070","volume":"3","author":"DW Felsher","year":"2003","unstructured":"Felsher, D. W. Cancer revoked: oncogenes as therapeutic targets. Nat. Rev. Cancer 3, 375\u2013380 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"16447_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1126\/science.1071489","volume":"297","author":"M Jain","year":"2002","unstructured":"Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102\u2013104 (2002).","journal-title":"Science"},{"key":"16447_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","volume":"8","author":"AG Letai","year":"2008","unstructured":"Letai, A. G. Diagnosing and exploiting cancer\u2019s addiction to blocks in apoptosis. Nat. Rev. Cancer 8, 121\u2013132 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"16447_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman, J. M. & Melo, J. V. Chronic myeloid leukemia\u2014advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451\u20131464 (2003).","journal-title":"N. Engl. J. Med."},{"key":"16447_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"16447_CR8","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1101\/gad.1609907","volume":"21","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214\u20133231 (2007).","journal-title":"Genes Dev."},{"key":"16447_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1101\/gad.1549407","volume":"21","author":"B Ancrile","year":"2007","unstructured":"Ancrile, B., Lim, K.-H. & Counter, C. M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714\u20131719 (2007).","journal-title":"Genes Dev."},{"key":"16447_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","volume":"18","author":"K Rakhra","year":"2010","unstructured":"Rakhra, K. et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 18, 485\u2013498 (2010).","journal-title":"Cancer Cell"},{"key":"16447_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever, R. M. et al. Myc cooperates with Ras by programming inflammation and immune suppression. Cell 171, 1301\u20131315.e14 (2017).","journal-title":"Cell"},{"key":"16447_CR12","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","volume":"171","author":"MJ Topper","year":"2017","unstructured":"Topper, M. J. et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell 171, 1284\u20131300.e21 (2017).","journal-title":"Cell"},{"key":"16447_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ccr.2009.12.043","volume":"17","author":"M Reimann","year":"2010","unstructured":"Reimann, M. et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 17, 262\u2013272 (2010).","journal-title":"Cancer Cell"},{"key":"16447_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","volume":"6","author":"A Sparmann","year":"2004","unstructured":"Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447\u2013458 (2004).","journal-title":"Cancer Cell"},{"key":"16447_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aac9935","volume":"352","author":"SC Casey","year":"2016","unstructured":"Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227\u2013231 (2016).","journal-title":"Science"},{"key":"16447_CR16","doi-asserted-by":"publisher","first-page":"14825","DOI":"10.1073\/pnas.0503039102","volume":"102","author":"MG Borrello","year":"2005","unstructured":"Borrello, M. G. et al. Induction of a proinflammatory program in normal human thyrocytes by the RET\/PTC1 oncogene. Proc. Natl Acad. Sci. USA 102, 14825\u201314830 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"16447_CR17","doi-asserted-by":"publisher","first-page":"1259425","DOI":"10.1126\/science.1259425","volume":"349","author":"MH Spitzer","year":"2015","unstructured":"Spitzer, M. H. et al. Immunology. An interactive reference framework for modeling a dynamic immune system. Science 349, 1259425 (2015).","journal-title":"Science"},{"key":"16447_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6057","volume":"5","author":"A Rehm","year":"2014","unstructured":"Rehm, A. et al. Dendritic cell-mediated survival signals in E\u03bc-Myc B-cell lymphoma depend on the transcription factor C\/EBP\u03b2. Nat. Commun. 5, 5057 (2014).","journal-title":"Nat. Commun."},{"key":"16447_CR19","doi-asserted-by":"publisher","first-page":"72818","DOI":"10.18632\/oncotarget.20350","volume":"8","author":"T Hirz","year":"2017","unstructured":"Hirz, T. et al. Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b\/ICAM-1 binding. Oncotarget 8, 72818\u201372834 (2017).","journal-title":"Oncotarget"},{"key":"16447_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3389\/fimmu.2016.00629","volume":"7","author":"E Pylaeva","year":"2016","unstructured":"Pylaeva, E., Lang, S. & Jablonska, J. The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils. Front. Immunol. 7, 629 (2016).","journal-title":"Front. Immunol."},{"key":"16447_CR21","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1182\/blood-2015-12-629089","volume":"127","author":"C Sun","year":"2016","unstructured":"Sun, C., Dotti, G. & Savoldo, B. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood 127, 3350\u20133359 (2016).","journal-title":"Blood"},{"key":"16447_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.trecan.2019.07.009","volume":"5","author":"MT Witkowski","year":"2019","unstructured":"Witkowski, M. T., Lasry, A., Carroll, W. L. & Aifantis, I. Immune-Based Therapies in Acute Leukemia. Trends in Cancer 5, 604\u2013618 (2019).","journal-title":"Trends in Cancer"},{"key":"16447_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"16447_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/1947601910377495","volume":"1","author":"MD Delgado","year":"2010","unstructured":"Delgado, M. D. & Le\u00f3n, J. Myc roles in hematopoiesis and leukemia. Genes Cancer 1, 605\u2013616 (2010).","journal-title":"Genes Cancer"},{"key":"16447_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri2154","volume":"7","author":"ND Huntington","year":"2007","unstructured":"Huntington, N. D., Vosshenrich, C. A. J. & Di Santo, J. P. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat. Rev. Immunol. 7, 703\u2013714 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"16447_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.it.2013.07.005","volume":"34","author":"J Yu","year":"2013","unstructured":"Yu, J., Freud, A. G. & Caligiuri, M. A. Location and cellular stages of natural killer cell development. Trends Immunol. 34, 573\u2013582 (2013).","journal-title":"Trends Immunol."},{"key":"16447_CR27","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1172\/JCI85413","volume":"126","author":"BL Mundy-Bosse","year":"2016","unstructured":"Mundy-Bosse, B. L. et al. MicroRNA-29b mediates altered innate immune development in acute leukemia. J. Clin. Invest. 126, 4404\u20134416 (2016).","journal-title":"J. Clin. Invest."},{"key":"16447_CR28","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood-2018-03-838474","volume":"132","author":"SD Scoville","year":"2018","unstructured":"Scoville, S. D. et al. Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132, 1792\u20131804 (2018).","journal-title":"Blood"},{"key":"16447_CR29","doi-asserted-by":"publisher","first-page":"5488","DOI":"10.1182\/blood-2008-10-187179","volume":"113","author":"L Chiossone","year":"2009","unstructured":"Chiossone, L. et al. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113, 5488\u20135496 (2009).","journal-title":"Blood"},{"key":"16447_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.4049\/jimmunol.176.3.1517","volume":"176","author":"Y Hayakawa","year":"2006","unstructured":"Hayakawa, Y. & Smyth, M. J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517\u20131524 (2006).","journal-title":"J. Immunol."},{"key":"16447_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.celrep.2014.12.025","volume":"10","author":"Y Kamimura","year":"2015","unstructured":"Kamimura, Y. & Lanier, L. L. Homeostatic control of memory cell progenitors in the natural killer cell lineage. Cell Rep. 10, 280\u2013291 (2015).","journal-title":"Cell Rep."},{"key":"16447_CR32","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni1132","volume":"5","author":"F Wang","year":"2004","unstructured":"Wang, F. et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5, 1266\u20131274 (2004).","journal-title":"Nat. Immunol."},{"key":"16447_CR33","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","volume":"178","author":"JB Swann","year":"2007","unstructured":"Swann, J. B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540\u20137549 (2007).","journal-title":"J. Immunol."},{"key":"16447_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991\u2013998 (2002).","journal-title":"Nat. Immunol."},{"key":"16447_CR35","doi-asserted-by":"publisher","first-page":"e111302","DOI":"10.1371\/journal.pone.0111302","volume":"9","author":"J Guan","year":"2014","unstructured":"Guan, J. et al. Role of type I interferon receptor signaling on NK cell development and functions. PLoS ONE 9, e111302 (2014).","journal-title":"PLoS ONE"},{"key":"16447_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4161\/onci.21284","volume":"1","author":"T Mizutani","year":"2012","unstructured":"Mizutani, T. et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 1, 1027\u20131037 (2012).","journal-title":"Oncoimmunology"},{"key":"16447_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"16447_CR38","first-page":"304","volume":"8","author":"L M\u00fcller","year":"2017","unstructured":"M\u00fcller, L., Aigner, P. & Stoiber, D. Type I interferons and natural killer cell regulation in cancer. Front. Immunol. 8, 304 (2017).","journal-title":"Front. Immunol."},{"key":"16447_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1084\/jem.20150712","volume":"213","author":"S Madera","year":"2016","unstructured":"Madera, S. et al. Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. J. Exp. Med. 213, 225\u2013233 (2016).","journal-title":"J. Exp. Med."},{"key":"16447_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature13537","volume":"511","author":"A Sab\u00f2","year":"2014","unstructured":"Sab\u00f2, A. et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511, 488\u2013492 (2014).","journal-title":"Nature"},{"key":"16447_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/nar\/29.2.397","volume":"29","author":"M Schuhmacher","year":"2001","unstructured":"Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397\u2013406 (2001).","journal-title":"Nucleic Acids Res."},{"key":"16447_CR42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/35070076","volume":"3","author":"P Staller","year":"2001","unstructured":"Staller, P. et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3, 392\u2013399 (2001).","journal-title":"Nat. Cell Biol."},{"key":"16447_CR43","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ncb1764","volume":"10","author":"M Wanzel","year":"2008","unstructured":"Wanzel, M. et al. A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat. Cell Biol. 10, 1051\u20131061 (2008).","journal-title":"Nat. Cell Biol."},{"key":"16447_CR44","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1073\/pnas.081074898","volume":"98","author":"AL Gartel","year":"2001","unstructured":"Gartel, A. L. et al. Myc represses the p21(WAF1\/CIP1) promoter and interacts with Sp1\/Sp3. Proc. Natl Acad. Sci. USA 98, 4510\u20134515 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"16447_CR45","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ijc.22372","volume":"120","author":"M Schlee","year":"2007","unstructured":"Schlee, M. et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt\u2019s lymphoma. Int. J. Cancer 120, 1387\u20131395 (2007).","journal-title":"Int. J. Cancer"},{"key":"16447_CR46","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa055351","volume":"354","author":"M Hummel","year":"2006","unstructured":"Hummel, M. et al. A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354, 2419\u20132430 (2006).","journal-title":"N. Engl. J. Med."},{"key":"16447_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ijc.2910170108","volume":"17","author":"L Zech","year":"1976","unstructured":"Zech, L., Haglund, U., Nilsson, K. & Klein, G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17, 47\u201356 (1976).","journal-title":"Int. J. Cancer"},{"key":"16447_CR48","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs, S. et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124, 3738\u20133747 (2014).","journal-title":"Blood"},{"key":"16447_CR49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.20110105","volume":"208","author":"E Clappier","year":"2011","unstructured":"Clappier, E. et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653\u2013661 (2011).","journal-title":"J. Exp. Med."},{"key":"16447_CR50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2141.2008.07314.x","volume":"143","author":"P Van Vlierberghe","year":"2008","unstructured":"Van Vlierberghe, P., Pieters, R., Beverloo, H. B. & Meijerink, J. P. P. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 143, 153\u2013168 (2008).","journal-title":"Br. J. Haematol."},{"key":"16447_CR51","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nri2304","volume":"8","author":"I Aifantis","year":"2008","unstructured":"Aifantis, I., Raetz, E. & Buonamici, S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat. Rev. Immunol. 8, 380\u2013390 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"16447_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1877-1173(10)92006-1","volume":"92","author":"CS Tremblay","year":"2010","unstructured":"Tremblay, C. S., Hoang, T. & Hoang, T. Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia. Prog. Mol. Biol. Transl. Sci. 92, 121\u2013156 (2010).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"16447_CR53","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1172\/JCI86489","volume":"126","author":"B Gerby","year":"2016","unstructured":"Gerby, B. et al. High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. J. Clin. Invest 126, 4569\u20134584 (2016).","journal-title":"J. Clin. Invest"},{"key":"16447_CR54","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1101\/gad.1450406","volume":"20","author":"AP Weng","year":"2006","unstructured":"Weng, A. P. et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia\/lymphoma. Genes Dev. 20, 2096\u20132109 (2006).","journal-title":"Genes Dev."},{"key":"16447_CR55","doi-asserted-by":"publisher","first-page":"17432","DOI":"10.1073\/pnas.1107303108","volume":"108","author":"PS Choi","year":"2011","unstructured":"Choi, P. S. et al. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc. Natl Acad. Sci. USA 108, 17432\u201317437 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"16447_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4049\/jimmunol.167.3.1179","volume":"167","author":"F Mattei","year":"2001","unstructured":"Mattei, F., Schiavoni, G., Belardelli, F. & Tough, D. F. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179\u20131187 (2001).","journal-title":"J. Immunol."},{"key":"16447_CR57","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1182\/blood.V99.9.3263","volume":"99","author":"M Montoya","year":"2002","unstructured":"Montoya, M. et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263\u20133271 (2002).","journal-title":"Blood"},{"key":"16447_CR58","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","volume":"26","author":"TF Gajewski","year":"2015","unstructured":"Gajewski, T. F. & Corrales, L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 26, 175\u2013178 (2015).","journal-title":"Cytokine Growth Factor Rev."},{"key":"16447_CR59","first-page":"7050","volume":"50","author":"DW Felsher","year":"1990","unstructured":"Felsher, D. W., Rhim, S. H. & Braun, J. A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines. Cancer Res. 50, 7050\u20137056 (1990).","journal-title":"Cancer Res."},{"key":"16447_CR60","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1002\/eji.201445375","volume":"45","author":"L Belting","year":"2015","unstructured":"Belting, L. et al. Critical role of the NKG2D receptor for NK cell-mediated control and immune escape of B-cell lymphoma. Eur. J. Immunol. 45, 2593\u20132601 (2015).","journal-title":"Eur. J. Immunol."},{"key":"16447_CR61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature 572, 254\u2013259 (2019).","journal-title":"Nature"},{"key":"16447_CR62","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41423-018-0011-5","volume":"15","author":"W Zou","year":"2018","unstructured":"Zou, W. Mechanistic insights into cancer immunity and immunotherapy. Cell. Mol. Immunol. 15, 419\u2013420 (2018).","journal-title":"Cell. Mol. Immunol."},{"key":"16447_CR63","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"16447_CR64","first-page":"1083","volume":"8","author":"X Tang","year":"2018","unstructured":"Tang, X. et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res. 8, 1083\u20131089 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"16447_CR65","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/leu.2013.279","volume":"28","author":"J Chu","year":"2014","unstructured":"Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo anti-tumor activity against human multiple myeloma. Leukemia 28, 917\u2013927 (2014).","journal-title":"Leukemia"},{"key":"16447_CR66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/cmi.2013.10","volume":"10","author":"M Cheng","year":"2013","unstructured":"Cheng, M., Chen, Y., Xiao, W., Sun, R. & Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 10, 230\u2013252 (2013).","journal-title":"Cell. Mol. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16447-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:54:28Z","timestamp":1670262868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-16447-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["16447"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-16447-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/503086","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2860"}}